StreetAlpha.app
Home › Stocks › ZYME

Zymeworks Inc. (ZYME)

$26.14
▼ −2.68%
LAST CLOSE · NOV 20

Zymeworks develops antibody medicines for cancer and immune diseases and partners with drugmakers to sell them. It last closed at $26.14 on Nov 20, down 2.68% on the day. The next earnings report for ZYME is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, ZYME reported EPS of $2.28 on revenue of $256.5M, with revenue up 828.7% from a year ago. Over its last 8 reports the stock moved an average of 3.3% the session after earnings. Over the last 12 months ZYME insiders bought $0 of stock on the open market and sold $6.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is ZYME in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ZYME.

Key Stats

Last 12 months
Results
Revenue
$266.0M
+97.8% vs a year ago
Net income
$43.3M
16.3% margin
EPS (diluted)
$0.53
Free cash flow
−$112.8M
−42.4% margin
Valuation
Market cap
$1.8B
69.0M shares
P/E
49.3
Price over 12 month EPS
Price to sales
6.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$100.5M
At Sep 30
Debt
$338.9M
At Sep 30
Shareholder equity
$258.3M
Buybacks
$165.6M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $26.7M$26.7MFY2021FY2022: $412.5M$412.5MFY2022FY2023: $76.0M$76.0MFY2023FY2024: $76.3M$76.3MFY2024FY2025: $106.0M$106.0MFY2025

From ZYME's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
$2.28
Quarter ended Sep 2026
Year ago EPS
-$0.26
Same quarter last year
Revenue
$256.5M
+828.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.32Dec '24Mar 2025: -$0.30Mar '25Jun 2025: $0.03Jun '25Sep 2025: -$0.26Sep '25Dec 2025: -$0.55Dec '25Mar 2026: -$0.59Mar '26Jun 2026: -$0.62Jun '26Sep 2026: $2.28Sep '26Latest $2.28
Revenue by quarter
Dec 2024: $31.0MDec '24Mar 2025: $27.1MMar '25Jun 2025: $48.7MJun '25Sep 2025: $27.6MSep '25Dec 2025: $2.5MDec '25Mar 2026: $2.4MMar '26Jun 2026: $4.6MJun '26Sep 2026: $256.5MSep '26Latest $256.5M
How ZYME moved after its last 8 reports
Average move the session after a report ±3.3%
Nov 9, 2026After the close+2.1%
Aug 6, 2026After the close+1.8%
May 7, 2026After the close−10.2%
Mar 2, 2026Time not announced+0.1%
Jan 12, 2026After the close+3.3%
Nov 6, 2025After the close−8.0%
Aug 7, 2025After the close−1.1%
May 8, 2025After the close−0.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ZYMEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ZYME
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ZYME

Technical Analysis

ZYME · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 8% below its 20 day and 4% below its 50 day average. It is 2% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the swing low (Sep 15) at $25.81, and the nearest resistance the swing high (May 27) at $26.19.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 5.5%/day
Key levels
$31.9752 week high+22.3%
$28.3620 day average+8.5%
$27.2050 day average+4.1%
$27.11Pivot R1+3.7%
$26.60Pivot+1.8%
$26.43100 day average+1.1%
$26.19Swing high (May 27)+0.2%
$26.14Last close
$25.81Swing low (Sep 15)−1.3%
$25.63Pivot S1−2.0%
$25.61200 day average−2.0%
$21.5252 week low−17.7%
Indicators
RSI (14)43.08Middle of its rangeNeutral
MACD-0.31Below its signal lineBearish
Stochastic20.9Middle of its rangeNeutral
ADX (14)19.3No clear trend
Williams %R-82.0Oversold below −80, overbought above −20Oversold
CCI (20)-87.4Oversold below −100, overbought above 100Neutral
Rate of change−11.8%Change over 10 sessionsBearish
ATR (14)$1.44Typical daily range, 5.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ZYME

What happened before

See how ZYME did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ZYME usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ZYME has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ZYMEHow many large options trades hit ZYME, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ZYME Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 83 selling
  • ▼Held by funds -1.3 pts
  • ●Funds holding -1
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding203204−0.5%
In funds' top 1043+33.3%
Held by funds99.5%100.8%−1.3 pts
New / increased28 / 7923 / 62+25.9%
Reduced / sold out55 / 2873 / 30−19.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZYME institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ZYME Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$6.4M11 sales · 6 insiders
2025-12 sold $1.3M2026-01 sold $3.4M2026-10 sold $358K2026-11 sold $1.4MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Scott PlatshonEVP, Chief Business OfficerSale15,292$24.95$382K
Nov 13Paul Andrew MooreChief Scientific OfficerSale39,741$26.07$1.0M
Oct 9Adam SchayowitzEVP, Head of R&DSale13,832$25.85$358K
Jan 12Mark HollywoodEVP & COOSale6,120$22.67$139K
Jan 12Kenneth GalbraithChair & CEOSale30,424$22.67$690K
Jan 12Paul Andrew MooreChief Scientific OfficerSale9,560$22.67$217K
Every insider buy and sale for ZYME over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ZYME insider trades →

From SEC Form 4 filings by ZYME's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZYME is in one of them and how their past ZYME trades turned out.

ZYME in the AI portfolios
Loading…

ZYME News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZYME in an article yet. Here's the latest on the wider market.

ZYME in the news

About Zymeworks

Zymeworks is a biotechnology company based in Middletown, Delaware. It develops medicines built from antibodies for cancer, inflammation and autoimmune disease, using its own technology platforms. Its partners are drugmakers that share development costs and sell the treatments, and Zymeworks earns milestone payments and royalties from those partnerships.

Headquarters
Middletown, DE
Founded
2003